Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial

Table 1 Adjuvant sorafenib for hepatocellular carcinoma

Ref.	Recruited period	Sample size (T/C)	HCC characteristics	First therapy	Adjuvant therapy	Outcomes
Li et al[6], 2016	2009-2013	12/24	With portal vein thrombus	Hepatic resection	Sorafenib (200-800 mg/d)	TTP, P = 0.041 OS, P = 0.01
Bruix et al[7], 2015	2008-2010	556/558	Early stage HCC	Hepatic resection or ablation	Sorafenib (400 mg) twice a day	RFS, P = 0.26 OS, P = 0.48
Lencioni et al[8], 2016	-	154/153	Intermediate stage multinodular HCC	TACE with doxorubicin-eluting beads	Sorafenib (400 mg) twice a day	TTP, P = 0.07 OS, P = 0.29
Kudo et al[9], 2011	2006-2009	229/227	Unresectable HCC who responded to TACE	Conventional TACE	Sorafenib (400 mg) twice a day	TTP, P = 0.25 OS, P = 0.79

C: Control group; HCC: Hepatocellular carcinoma; OS: Overall survival; RFS: Recurrence-free survival; T: Adjuvant treated group; TACE: Transarterial chemoembolization; TTP: Time-to-tumor progression.